These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 16760454)

  • 1. Maintenance treatment of depression in old age.
    Edwards JL
    N Engl J Med; 2006 Jun; 354(23):2505-6; author reply 2505-6. PubMed ID: 16760454
    [No Abstract]   [Full Text] [Related]  

  • 2. Sexual function during bupropion or paroxetine treatment of major depressive disorder.
    Kennedy SH; Fulton KA; Bagby RM; Greene AL; Cohen NL; Rafi-Tari S
    Can J Psychiatry; 2006 Mar; 51(4):234-42. PubMed ID: 16629348
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bupropion sustained release versus paroxetine for the treatment of depression in the elderly.
    Weihs KL; Settle EC; Batey SR; Houser TL; Donahue RM; Ascher JA
    J Clin Psychiatry; 2000 Mar; 61(3):196-202. PubMed ID: 10817105
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Geriatric depression treatment in nonresponders to selective serotonin reuptake inhibitors.
    Whyte EM; Basinski J; Farhi P; Dew MA; Begley A; Mulsant BH; Reynolds CF
    J Clin Psychiatry; 2004 Dec; 65(12):1634-41. PubMed ID: 15641868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Maintenance treatment of depression in old age.
    Bajbouj M; Danker-Hopfe H
    N Engl J Med; 2006 Jun; 354(23):2505-6; author reply 2505-6. PubMed ID: 16764055
    [No Abstract]   [Full Text] [Related]  

  • 6. Relative antidepressant efficacy of bupropion and the selective serotonin reuptake inhibitors in major depressive disorder: gender-age interactions.
    Papakostas GI; Kornstein SG; Clayton AH; Soares CN; Hallett LA; Krishen A; Tucker VL
    Int Clin Psychopharmacol; 2007 Jul; 22(4):226-9. PubMed ID: 17519646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paroxetine/bupropion combination treatment for refractory depression.
    Marshall RD; Liebowitz MR
    J Clin Psychopharmacol; 1996 Feb; 16(1):80-1. PubMed ID: 8834426
    [No Abstract]   [Full Text] [Related]  

  • 8. Effectiveness of mirtazapine as add-on to paroxetine
    Xiao L; Zhu X; Gillespie A; Feng Y; Zhou J; Chen X; Gao Y; Wang X; Ma X; Gao C; Xie Y; Pan X; Bai Y; Xu X; Wang G; Chen R
    Psychol Med; 2021 May; 51(7):1166-1174. PubMed ID: 31931894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of evidence-based pharmacotherapy or cognitive behavior therapy compared with community referral for major depression in predominantly low-income minority women.
    Revicki DA; Siddique J; Frank L; Chung JY; Green BL; Krupnick J; Prasad M; Miranda J
    Arch Gen Psychiatry; 2005 Aug; 62(8):868-75. PubMed ID: 16061764
    [TBL] [Abstract][Full Text] [Related]  

  • 10. When Discontinuing SSRI Antidepressants Is a Challenge: Management Tips.
    Jha MK; Rush AJ; Trivedi MH
    Am J Psychiatry; 2018 Dec; 175(12):1176-1184. PubMed ID: 30501420
    [No Abstract]   [Full Text] [Related]  

  • 11. Selective serotonin reuptake inhibitors in familial Mediterranean fever: are we treating depression or inflammation?
    Ozçakar L; Onat AM; Kaymak SU; Ureten K; Akinci A
    Rheumatol Int; 2005 May; 25(4):319-20. PubMed ID: 15449025
    [No Abstract]   [Full Text] [Related]  

  • 12. Paxil (paroxetine) lifts depression, lowers associated anxiety symptoms.
    Adv Nurse Pract; 1997 Oct; 5(10):71. PubMed ID: 9459990
    [No Abstract]   [Full Text] [Related]  

  • 13. Nonadherence to paroxetine: a study based on monitoring plasma paroxetine levels.
    Yoshimura R; Ikenouchi-Sugita A; Umene-Nakano W; Hori H; Ueda N; Nakamura J
    J Clin Psychopharmacol; 2010 Feb; 30(1):82-3. PubMed ID: 20075657
    [No Abstract]   [Full Text] [Related]  

  • 14. Triiodothyronine addition to paroxetine in the treatment of major depressive disorder.
    Appelhof BC; Brouwer JP; van Dyck R; Fliers E; Hoogendijk WJ; Huyser J; Schene AH; Tijssen JG; Wiersinga WM
    J Clin Endocrinol Metab; 2004 Dec; 89(12):6271-6. PubMed ID: 15579788
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quality of life in geriatric depression: a comparison of remitters, partial responders, and nonresponders.
    Doraiswamy PM; Khan ZM; Donahue RM; Richard NE
    Am J Geriatr Psychiatry; 2001; 9(4):423-8. PubMed ID: 11739069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Benefits and harms of pediatric antidepressant medications.
    Edwards JL; Kirk KK; Midha CK
    JAMA; 2007 Aug; 298(6):626-7; author reply 627. PubMed ID: 17684183
    [No Abstract]   [Full Text] [Related]  

  • 17. Resolution of sleepiness and fatigue: a comparison of bupropion and selective serotonin reuptake inhibitors in subjects with major depressive disorder achieving remission at doses approved in the European Union.
    Cooper JA; Tucker VL; Papakostas GI
    J Psychopharmacol; 2014 Feb; 28(2):118-24. PubMed ID: 24352716
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinically relevant pharmacokinetic interaction between venlafaxine and bupropion: a case series.
    Paslakis G; Gilles M; Deuschle M
    J Clin Psychopharmacol; 2010 Aug; 30(4):473-4. PubMed ID: 20631572
    [No Abstract]   [Full Text] [Related]  

  • 19. Differential effects of milnacipran, fluvoxamine and paroxetine for depression, especially in gender.
    Morishita S; Arita S
    Eur Psychiatry; 2003 Dec; 18(8):418-20. PubMed ID: 14680720
    [No Abstract]   [Full Text] [Related]  

  • 20. Treatment of mild depression in elderly patients.
    Terluin B; van Hout H
    JAMA; 2000 Dec; 284(23):2993-4; author reply 2994. PubMed ID: 11122575
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.